Cell Biol Int Lymphopenia in COVID-19: Therapeutic Opportunities

[tetano]

Cell Biol Int


. 2020 May 27.
doi: 10.1002/cbin.11403. Online ahead of print.
Lymphopenia in COVID-19: Therapeutic Opportunities


Nazanin Fathi ^{1 2} , Nima Rezaei ^{1 2 3}



Affiliations

• PMID: 32458561
• DOI: 10.1002/cbin.11403

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is uncontrollably spread all over the world. The host immune responses strongly try to confront it with all the potential cells and cytokines. With chronically condition of SARS-CoV-2, NK cells and T cells become exhausted and decreasing their count leads to lymphopenia. Inability to eradicate the infected organ makes hyper-initiation of the immune system, which releases the excessive inflammatory cytokines to compensate the exhausted one as well as the low lymphocytes counts; it consequently lead to the cytokine storm syndrome. These mechanisms and the potential therapeutic targeting are discussed in this paper. This article is protected by copyright. All rights reserved.

Keywords: Apoptosis; COVID-19; Coronavirus; Cytokine Storm Syndrome; Hypercytokinemia; Inflammation; Lymphopenia; Therapeutic.